Kidney transplant monitoring by anti donor specific antibodies

Abstract

Donor‐specific anti‐HLA antibodies were studied by cytotoxicity crossmatching (CTXM) and flow cytometry crossmatching (FCXM) in 117 kidney transplant candidates; the same study was carried out in 33 cadaver‐donor kidney recipients, during the first 3 post‐transplant months, for which donor cells were available. Pre‐transport evaluation showed that 82.9 % of subjects were CTXM negative/FCXM negative, 6.8 % of patients were positive in both tests, and 10.3 % were CTXM negative/FCCM positive. Post‐transplant monitoring for donor‐specific antibodies (Abs‐DS) showed that nine recipients (27.3 %) were FCXM positive; six of them were IgG + and three IgM +. In comparing these results with the clinical course, a significant association between FCXM IgG + and rejection episodes was observed (P < 0.01).

The Presence of HLA-Directed Antibodies after Heart Transplantation Is Associated with Poor Allograft Outcome

“…Most of published studies focused on renal transplant recipients. A high correlation has been demonstrated between the development of HLA-directed antibodies after kidney transplant and acute or chronic allograft rejection (3)(4)(5)(6)(7)(8)(9). However, little information is available for heart allograft recipients.…”